NHS Halts Hormone Treatment for Questioning Teens Amid Evidence Concerns

NHS England has declared a pause on new dispensing of cross-sex hormones for 16 and 17-year-olds exploring gender identity questions, in the wake of a comprehensive review that determined previous research into the drugs’ safety and effectiveness was inadequate. The decision, which comes into force right away, comes after an independent evidence review commissioned by the health service determined there was insufficient high-quality evidence to determine whether the hormones help or damage teenagers. Teenagers already receiving the treatment will continue their prescriptions, though clinicians will be required to assess their cases. NHS England said a limited number of teenagers would be affected by the pause and will be provided with other treatment options at three NHS gender clinics for children serving England.

The Decision and Its Reach

The pause represents a significant shift in NHS England’s handling of gender-affirming medical care for teenagers. Cross-sex hormones, which help individuals develop physical characteristics linked to their desired gender, can result in permanent alterations including a lower voice, breast development, or other lasting changes. The choice to pause new prescriptions stems from the NHS’s review that existing evidence cannot clearly demonstrate whether these treatments help or harm young people dealing with gender dysphoria. Professor James Palmer, National Medical Director for Specialised Services at NHS England, stressed that the review had been “exceptionally thorough and complex,” eventually finding that existing evidence fails to support continued use of masculinising or feminising hormone treatments for young people under 18.

NHS England has launched a 90-day consultation process commencing Monday to collect additional feedback on the revised policy and review findings. The health service hopes this consultation period will identify any evidence that could have been missed during the original review. Current guidance already banned prescriptions for under-16s seeking gender treatment, so the new suspension effectively extends restrictions to include 16 and 17-year-olds. The NHS emphasized its commitment to providing full support, stating that young people unable to access hormone therapy will be provided with alternative care options through its three specialized gender clinics for children across England.

• Pause applies to initial prescriptions for 16 and 17-year-olds only
• Young people already on hormones will proceed with existing treatment
• Clinicians will review active cases for ongoing suitability
• Alternative care accessible at three NHS gender clinics across the country

Evidence Assessment Results

The choice to pause hormone prescriptions originates from a thorough evidence assessment commissioned by NHS England, which assessed the scientific foundation for cross-sex hormone treatment in young people. The assessment, comprising ten independent assessments of different aspects of testosterone and oestrogen use, revealed significant gaps in the evidence supporting existing clinical practice. NHS England determined that the existing evidence was insufficient to establish whether these therapies help or harm adolescents experiencing gender dysphoria, rendering it unfeasible to justify continuing new prescriptions with confidence in their safety and efficacy.

This observation supports worries expressed in Dr Hilary Cass’s substantial April 2024 review on children’s gender care, which noted “remarkably weak” research regarding clinical treatments in this domain. The Cass review led NHS England to undertake its own comprehensive analysis of the research foundation. The resulting assessment focused on multiple outcomes for young patients, such as wellbeing quality, psychological wellbeing, and general wellbeing. Rather than awaiting additional evidence to surface, NHS England opted to adopt a conservative stance, suspending new prescriptions while continuing to review input from advocacy groups and healthcare professionals.

What the Data Revealed

The 10 separate evidence reviews examined the impact of hormone hormones across a range of health and psychological outcomes for adolescents with a gender identity different from their sex at birth. Researchers evaluated existing literature on how these treatments affected life quality, mental health status, and distress related to gender identity among adolescents. The review was intentionally thorough, aiming to leave no stone unturned in evaluating whether sufficient evidence existed to support ongoing prescription for individuals under 18 years old.

The overarching conclusion was stark: the available evidence did not reach the level required to with certainty endorse hormone treatment for this demographic. Professor Palmer indicated that the review “demonstrated that the available evidence does not endorse the sustained use of hormone treatments” to treat young people under 18 with gender-related conditions. This finding indicated NHS England could not determine whether the treatments were harmful or effective, calling for a suspension subject to further clarification and professional consultation.

• Ten separate evaluations assessed multiple facets of hormone treatment
• Investigation examined life quality and psychological results
• Available evidence found limited to support ongoing treatment
• Unable to establish if treatments damage or benefit adolescents

Responses and Legal Challenges

The NHS decision to suspend hormone prescriptions has triggered swift and polarised responses from across the healthcare and advocacy sectors. Trans advocacy groups have expressed strong opposition to the policy change, with some organisations indicating their plans to take legal proceedings against NHS England. These groups argue that the pause limits availability to transformative treatment for adolescents experiencing gender dysphoria, and contend that the evidence review does not support such a restrictive approach. The consultation period starting Monday will be vital in determining whether NHS England’s stance shifts or strengthens based on stakeholder feedback.

Healthcare practitioners employed in gender identity care have also shared their views on the decision, with views ranging from cautious support to substantial concerns. Some healthcare providers welcome the evidence evaluation as a necessary step to confirm treatments are adequately supported, while others express concern that the pause may negatively affect vulnerable young people who have already begun hormone therapy or are waiting to access care. The 90-day consultation period constitutes an opportunity for these diverse voices to formally present their perspectives, conceivably shaping whether the temporary pause becomes permanent policy or is revised based on emerging research or professional consensus.

Advocacy Coalition Response

Trans advocacy bodies have criticised the NHS pause as discriminatory in nature and potentially damaging to vulnerable young people. These groups maintain that the choice to stop fresh prescriptions contradicts the experiences of transgender adolescents who describe enhanced mental wellbeing and standard of living following hormone treatment. They contend that the assessment’s conclusion of “weak evidence” does not justify such a limiting approach, and that the pause essentially prevents care to people with the greatest need while pending complete scientific confirmation that might never emerge.

Lawsuits seem probable, with civil rights organisations suggesting they plan to pursue legal proceedings to challenge or alter the treatment suspension. These bodies argue that the decision violates the rights of adolescents to obtain proper treatment and might represent discrimination based on gender identification. They highlight that individual clinical assessments ought to decide treatment eligibility rather than universal prohibitions, and that the engagement process should carefully examine accounts from trans communities directly about lived experiences with hormonal treatment.

Commercial Sector and International Context

While NHS England puts in place its cautious approach, the private medical industry in the UK continues to offer hormone treatments to teenagers outside the public health system. This establishes a two-tier system where affluent households may obtain treatments that the NHS has put on hold, generating questions about equity and access. The difference between NHS policy and private healthcare delivery highlights fundamental issues about how evidence-based recommendations should work across different healthcare settings, and whether young people’s access to gender-affirming care should rest on their family’s economic circumstances rather than clinical requirement.

Internationally, healthcare systems have adopted varying approaches to hormone treatment for questioning adolescents. Some European countries, including Sweden and Finland, have similarly tightened restrictions on gender-affirming hormones for minors in the past several years, citing insufficient evidence. Conversely, other nations maintain more permissive treatment guidelines, with some medical organisations contending that denying treatment causes greater psychological harm. These divergent international responses underscore the genuine scientific uncertainty regarding the lasting impacts and advantages of these interventions, and suggest that consensus has not yet emerged among global medical authorities on the suitable course of treatment for adolescents with gender dysphoria.

• Private clinics in the UK persist in providing hormone treatments to minors despite NHS pause
• Finland and Sweden have likewise limited hormonal medications for minors in recent years
• International health bodies remain divided on suitable therapeutic approaches for adolescents

The Next Steps

NHS England has initiated a systematic approach to determine its long-range strategy on hormonal therapy for teenagers questioning their gender. A three-month public engagement started on Monday will seek input from patient representatives, healthcare professionals, and the wider public on the evidence review findings and proposed revised guidance. The health service has emphasised that this feedback phase is essential for uncovering any information missed during initial review during the first review stage. The outcomes will influence whether the existing moratorium on new prescriptions becomes long-term policy or whether treatment restarts under adjusted guidelines.

During the assessment window, NHS England will keep monitoring and supporting young people already receiving hormone treatment, with clinicians performing individual assessments of each patient’s care pathway. The three current NHS gender clinics for children will expand their provision of alternative care options for those unable to access hormones, including psychological services and therapeutic support. After the 90-day period, NHS England will assess all input received and reach a final determination regarding long-term policy. This decision will have major consequences for thousands of young people across England pursuing gender-affirming treatment.

The 90 Day Advisory Process

The consultation constitutes a official chance for stakeholders to challenge or support NHS England’s preliminary findings. Campaign organisations, healthcare practitioners, and members of the general public can provide evidence and viewpoints on whether the review accurately reflects existing scientific knowledge. Trans advocacy organisations have previously signalled they may pursue legal action, suggesting the consultation will be disputed. NHS England has indicated it will thoroughly examine all responses, specifically aiming to find any robust evidence that the initial review may have missed or underweighted in its assessment.

The 90-day window is designed to balance the requirement for detailed review with the urgency of offering clear guidance to young people and medical professionals presently unclear about available treatments. NHS England will collect and review all consultation responses before publishing its final decision on new guidance. This longer timeframe permits clinicians to express practical experience, research institutions to present further data, and youth themselves to explain how the revised policies affect their overall health and wellbeing.